AstraZeneca PLC - ADR

$178.76

up-down-arrow $-3.51 (-1.93%)

As on 18-Nov-2026 16:00EST

Market cap

info icon

$286,067 Mln

Revenue (TTM)

info icon

$62,168 Mln

P/E Ratio

info icon

26.1

P/B Ratio

info icon

5.5

Div. Yield

info icon

1.8 %

AstraZeneca - ADR Share Price

Compare

High: Low: Return:

High: Low: Return:

Max: Min: Median:

Max: Min: Median:

loading...
loading...
loading...
loading...
loading...
loading...
loading...
loading...

Stock Range

Today’s Range

Low: 178.29 High: 181.50

52 Week Range

Low: 153.41 High: 196.41

Liquidityliquidity Low

Low Moderate High

Fundamentals

  • Net Profit (TTM)Net Profit (TTM) information

    $2,326 Mln

  • ROEROE information

    0.2 %

  • ROCEROCE information

    13.7 %

  • Industry P/EIndustry P/E information

    --

  • EV/EBITDAEV/EBITDA information

    14.8

  • Debt to EquityDebt to Equity information

    0.5

  • Book ValueBook Value information

    $--

  • EPSEPS information

    $7

  • Face valueFace value information

    --

  • Shares outstandingShares outstanding information

    1,550,917,690

10 Years Aggregate

CFO

$54,607.00 Mln

EBITDA

$79,906.00 Mln

Net Profit

$26,599.00 Mln

Performance

Company
YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
AstraZeneca - ADR
-- 8.1 13.9 -- -- -- --
BSE Sensex*
-2.5 10.5 6.9 -2.5 7.9 6.7 12.2
S&P 100
4.0 -5.5 -5.9 6.6 19.0 10.7 14.1
As on 18-Nov-2026  |  *As on 19-Nov-2026
The underlying data is unavailable.

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details
loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

loading...

*All values are in ($ Mln)

Key Ratios

View Details
loading...

loading...

loading...

5Y Avg -- 3Y Avg -- TTM --

loading...

P/E Ratio

--

--Min --Median --Max

loading...

P/B Ratio

--

--Min --Median --Max

loading...

Earnings Yield (%)

--

Earnings Yield (%) = EBIT / Enterprise value

PEG Ratio

--

Price = Price / Earnings to growth ratio

loading...

loading...

loading...

Peers

View Details
Company
Price ($) Market Cap ($ Mln) Revenue (TTM) Net Profit (TTM) OPM (%) ROE (%) P/E P/B
AstraZeneca - ADR
178.8 286,066.7 62,168.2 10,988.5 24.1 22.2 26.1 5.5
25.2 89,343.3 123,005.0 11,316.0 14.8 13 8 1.0
65.6 38,856.1 17,959.0 2,029.0 21.4 16.9 14.6 2.2
58.7 25,776.3 17,959.0 2,029.0 21.4 16.9 12.5 2.0
2.3 2,342.3 57,193.7 -6,140.9 13.3 -6.7 -- 0.4
53.0 3,293.3 763.1 -84.4 -7.1 -2 -- 6.3
103.1 26,560.5 4,480.0 558.0 24.0 7.2 102.3 3.4
107.3 27,759.6 4,480.0 558.0 24.0 7.2 106.9 3.5
181.6 42,458.4 27,878.4 151.1 4.0 -- -- 93.0
160.5 23,933.8 5,500.5 513.7 9.8 18 46.3 7.9

Shareholding Pattern

View Details
loading...

About AstraZeneca - ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...  Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom. 

  • CEO & Executive Director

    Mr. Pascal Soriot D.V.M., M.B.A.

  • CEO & Executive Director

    Mr. Pascal Soriot D.V.M., M.B.A.

  • Headquarters

    Cambridge

  • Website

    https://www.astrazeneca.com

FAQs for AstraZeneca - ADR

The share price of AstraZeneca PLC - ADR is $178.76 (NYSE) and $178.76 (NASDAQ) as of 18-Nov-2026 16:00 EST. AstraZeneca PLC - ADR has given a return of --% in the last 1 years.

The P/E ratio of AstraZeneca PLC - ADR is 26.09 times as on 13-Nov-2026.
The P/B ratio of AstraZeneca PLC - ADR is 5.53 times as on 13-Nov-2026, a 837 premium to its peers’ median range of 0.59 times.


PE & PB ratio at the end of financial year.


Year P/E Ratio P/B Ratio
2025
14.00
2.95
2024
14.55
2.51
2023
17.65
2.69
2022
32.15
2.85
2021
804.58
2.29

The 52-week high and low of AstraZeneca PLC - ADR are Rs 196.41 and Rs 153.41 as of 19-Nov-2026.

AstraZeneca PLC - ADR has a market capitalisation of $ 286,067 Mln as on 13-Nov-2026. As per SEBI classification, it is a Large Cap company.

Before investing in AstraZeneca PLC - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.
Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.

loading...
loading...

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month